Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

17/86 subjects), with no

differences among the active drug group and the placebo group

* Plasma levels of larazotide acetate were below the limits of

quantification (0.5 ng/ml) in all groups at days 0, 7 and 14

"Although the primary study outcome was not statistically significant, a great deal was learned about the potential effects of larazotide acetate and the secondary outcome data is very positive. Further, important new information was gained about the best way to run a celiac disease clinical trial. This trial marks the beginning of a new era in celiac therapeutics where modalities beyond diet alone have the ability to improve the lives of our patients," stated Daniel Leffler, MD a gastroenterologist from Beth Israel Deaconess Medical Center.

"We are very encouraged by the clear trend in the reduction of intestinal permeability and the signs and symptoms of gluten exposure in patients with celiac disease. We have applied the knowledge gained in this Phase IIa clinical trial to a larger Phase IIb gluten challenge study which is currently ongoing. In addition, we have recently initiated a clinical trial in 106 active celiac disease patients. Alba is committed to developing and studying new treatment options for patients with celiac disease," stated Dr. Francisco Leon, Head of Clinical Research and Development at Alba. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Celiac Disease

Celiac disease is a lifelong T-cell mediated auto-immune disorder, which occurs in individuals who are genetically susceptible and is characterized by small intestinal inflammation, injury and intolerance to gluten. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. People with CD cannot tole
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rq47bp/global_pressure ... Pressure Relief Devices Market 2015-2019" report to their ... to grow at a CAGR of 4.41% over the ... Market 2015-2019, has been prepared based on an in-depth ... covers the Americas, and the APAC and EMEA; it ...
(Date:7/27/2015)... , July 27, 2015  QT Vascular Ltd., ... a global company engaged in the design, assembly and ... treatment of vascular disease, has entered into an agreement ... to US$13.14 million convertible bond investment. This funding will ... its growth to the next milestone. ...
(Date:7/27/2015)... July 27, 2015  Array BioPharma Inc. ... for the fourth quarter and full year ... call to discuss those results on Monday, ... Officer will lead the call. ... 464-3927Toll:(765) 507-2598Pass Code: 68380312 Webcast, including Replay ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3
(Date:7/27/2015)... ... July 27, 2015 , ... Writing Effective Standard Operating ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/writingeffectivesops ... will look at during an inspection. Yet, in 2014, "inadequate SOPs" was ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece published ... side of plastic surgery and explained why people should not shy away from their ... the excesses of the few and celebrate it for the modern wonder that it ...
(Date:7/27/2015)... ... ... Looking to brush up on all the things you should be doing ... enhanced its Dental webpage with new materials, including user-friendly, educational videos, to help members ... to offering our 3.8 million members tools and resources to help them keep a ...
(Date:7/27/2015)... , ... July 27, 2015 , ... North Central Surgical ... , The center invites all those prospective joint-replacement patients, along with their friends ... of each month, with Monday classes (Aug 6, Sept 8 [Tue due to Labor ...
(Date:7/27/2015)... York, NY (PRWEB) , ... July 27, 2015 ... ... in enterprise communications, including emergency notification and mobile collaboration, ... a new graphical user interface, language localization and other feature enhancements. , This ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2
... PITTSBURGH, March 31 More than twice as many lungs ... transplant operations if intensive care physicians were to work ... donor bodies after brain death has occurred, according to an ... physicians that is now in the online version of the ...
... (HealthDay News) -- An antibacterial agent that,s an ingredient in ... the bodies of fish, finds a new study. The ... due to its potential hormone-disrupting effects. Bioaccumulation occurs when ... to metabolize and excrete the chemical quickly enough, allowing it ...
... Germany, Thursday 31 March 2011- New data presented at the ... interactions between T cells and hepatocytes that are regulated ... HCV persists in the liver. , The nature ... and cytokine expression, and may have an impact on ...
... Dotinga HealthDay Reporter , WEDNESDAY, March 30 (HealthDay ... obese seniors lose weight and stay fit much better than ... finding may sound obvious, but the lead author of the ... people over 65. In fact, some physicians worry about ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, March ... as often as low-quality nursing homes, a new study shows. ... threat of litigation, doesn,t lead to improvements in patient care. ... rewarded for superior care in terms of fewer lawsuits. ...
... increase of daylight hours have long been thought to ... migration. Scientists at the Smithsonian Conservation Biology Institute, however, ... Researchers have focused on how warming trends in temperate ... This new research shows that changes in rainfall on ...
Cached Medicine News:Health News:More organs for transplant when icu docs help take care of brain dead donors, says UPMC 2Health News:Antibacterial Soap Additive Accumulates in Fish: Study 2Health News:Diet-Exercise Combo Seems to Work Best for Obese Seniors 2Health News:Lawsuits Aren't Improving Nursing Home Care: Study 2Health News:Lawsuits Aren't Improving Nursing Home Care: Study 3Health News:Lawsuits Aren't Improving Nursing Home Care: Study 4Health News:Smithsonian scientists find declining rainfall is a major influence for migrating birds 2Health News:Smithsonian scientists find declining rainfall is a major influence for migrating birds 3
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: